- Home
- CCIF vs ATOS Comparison
CCIF vs ATOS Comparison
Compare CCIF & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- ATOS
- Stock Information
- Founded
- CCIF 2011
- ATOS 2009
- Country
- CCIF United States
- ATOS United States
- Employees
- CCIF N/A
- ATOS N/A
- Industry
- CCIF Finance/Investors Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- ATOS Health Care
- Exchange
- CCIF Nasdaq
- ATOS Nasdaq
- Market Cap
- CCIF 113.2M
- ATOS 112.5M
- IPO Year
- CCIF N/A
- ATOS 2012
- Fundamental
- Price
- CCIF $6.56
- ATOS $0.78
- Analyst Decision
- CCIF
- ATOS Strong Buy
- Analyst Count
- CCIF 0
- ATOS 3
- Target Price
- CCIF N/A
- ATOS $7.13
- AVG Volume (30 Days)
- CCIF 76.9K
- ATOS 713.7K
- Earning Date
- CCIF 01-01-0001
- ATOS 05-13-2025
- Dividend Yield
- CCIF 25.90%
- ATOS N/A
- EPS Growth
- CCIF N/A
- ATOS N/A
- EPS
- CCIF N/A
- ATOS N/A
- Revenue
- CCIF N/A
- ATOS N/A
- Revenue This Year
- CCIF N/A
- ATOS N/A
- Revenue Next Year
- CCIF N/A
- ATOS N/A
- P/E Ratio
- CCIF N/A
- ATOS N/A
- Revenue Growth
- CCIF N/A
- ATOS N/A
- 52 Week Low
- CCIF $7.43
- ATOS $0.55
- 52 Week High
- CCIF $10.16
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- CCIF 42.31
- ATOS 44.02
- Support Level
- CCIF $6.63
- ATOS $0.78
- Resistance Level
- CCIF $6.61
- ATOS $1.07
- Average True Range (ATR)
- CCIF 0.09
- ATOS 0.07
- MACD
- CCIF 0.00
- ATOS -0.02
- Stochastic Oscillator
- CCIF 24.56
- ATOS 13.80
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.